Craig Sauter
Overview
Explore the profile of Craig Sauter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
2468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Danilov A, Sauter C, Phillips T, Coombs C, Ip A, Wang Y, et al.
Clin Lymphoma Myeloma Leuk
. 2025 Feb;
PMID: 39919997
Recent years have brought a much-needed paradigm shift to the management and treatment of mature B-cell lymphomas. Pathophysiologic and clinical heterogeneity within the various subtypes have historically contributed to treatment...
2.
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit R, Salit R, et al.
Blood Adv
. 2024 Nov;
9(4):797-807.
PMID: 39561372
The aim of our study was to analyze the potential survival benefit associated with hematopoietic stem cell transplantation (HSCT) according to clinicobiological scores, which incorporate mutation-enhanced international prognostic score system...
3.
Goyal A, OLeary D, Dabaja B, Weng W, Zain J, Cutler C, et al.
Transplant Cell Ther
. 2024 Sep;
30(11):1047-1060.
PMID: 39222792
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience...
4.
Cancilla D, Nurse D, Wei W, Cenin D, Ferraro C, DAndrea C, et al.
Ann Hematol
. 2024 Aug;
103(12):6027-6030.
PMID: 39136773
No abstract available.
5.
Pophali P, Fein J, Ahn K, Allbee-Johnson M, Ahmed N, Awan F, et al.
Blood Adv
. 2024 Jul;
8(20):5290-5296.
PMID: 38985302
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19-directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. We...
6.
Shadman M, Ahn K, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, et al.
Blood Cancer J
. 2024 Jul;
14(1):108.
PMID: 38977682
In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We...
7.
Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, et al.
Transplant Cell Ther
. 2024 Jun;
30(8):790.e1-790.e16.
PMID: 38834151
Idecabtagene vicleucel (ide-cel) has shown impressive efficacy in relapsed/refractory multiple myeloma (RRMM). This study aimed to investigate the impact of absolute lymphocyte count (ALC) on the survival outcomes of RRMM...
8.
Epperla N, Hashmi H, Ahn K, Allbee-Johnson M, Chen A, Wirk B, et al.
Br J Haematol
. 2024 May;
205(3):1202-1207.
PMID: 38797526
No abstract available.
9.
Wang T, Ahn K, Shadman M, Kaur M, Ahmed N, Bacher U, et al.
Leukemia
. 2024 May;
38(7):1564-1569.
PMID: 38750138
CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response...
10.
Stuver R, Mian A, Brown S, Devlin S, Caimi P, Chinapen S, et al.
Am J Hematol
. 2024 Mar;
99(6):1180-1183.
PMID: 38526002
No abstract available.